Aligos Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aligos Therapeutics's earnings have been declining at an average annual rate of -1.2%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 38.1% per year.
Key information
-1.2%
Earnings growth rate
72.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 38.1% |
| Return on equity | -112.7% |
| Net Margin | -950.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aligos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -76 | 25 | 0 |
| 31 Mar 24 | 14 | -100 | 28 | 0 |
| 31 Dec 23 | 16 | -88 | 30 | 0 |
| 30 Sep 23 | 16 | -82 | 31 | 0 |
| 30 Jun 23 | 17 | -82 | 30 | 0 |
| 31 Mar 23 | 14 | -83 | 28 | 0 |
| 31 Dec 22 | 14 | -96 | 26 | 0 |
| 30 Sep 22 | 11 | -112 | 29 | 0 |
| 30 Jun 22 | 8 | -126 | 30 | 0 |
| 31 Mar 22 | 6 | -136 | 29 | 0 |
| 31 Dec 21 | 4 | -128 | 29 | 0 |
| 30 Sep 21 | 4 | -125 | 25 | 0 |
| 30 Jun 21 | 2 | -125 | 23 | 0 |
| 31 Mar 21 | 1 | -116 | 20 | 0 |
| 31 Dec 20 | 0 | -109 | 18 | 0 |
| 30 Sep 20 | 0 | -92 | 15 | 15 |
| 30 Jun 20 | 0 | -73 | 14 | 27 |
| 31 Mar 20 | 0 | -62 | 12 | 35 |
| 31 Dec 19 | 0 | -52 | 10 | 44 |
Quality Earnings: 5WK0 is currently unprofitable.
Growing Profit Margin: 5WK0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5WK0 is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare 5WK0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5WK0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 5WK0 has a negative Return on Equity (-112.65%), as it is currently unprofitable.